Search

Your search keyword '"Amidei, Christina"' showing total 254 results

Search Constraints

Start Over You searched for: Author "Amidei, Christina" Remove constraint Author: "Amidei, Christina"
254 results on '"Amidei, Christina"'

Search Results

1. Ultrasound-mediated delivery of doxorubicin to the brain results in immune modulation and improved responses to PD-1 blockade in gliomas

3. Translocon-associated Protein Subunit SSR3 Determines and Predicts Susceptibility to Paclitaxel in Breast Cancer and Glioblastoma.

4. Age-stratified comorbid and pharmacologic analysis of patients with glioblastoma

5. Proceedings of the Survivorship Care in Neuro-Oncology Workshop sponsored by the Comprehensive Oncology Network Evaluating Rare CNS Tumors (NCI-CONNECT).

6. ERK1/2 phosphorylation predicts survival following anti-PD-1 immunotherapy in recurrent glioblastoma

7. Repeated blood–brain barrier opening with an implantable ultrasound device for delivery of albumin-bound paclitaxel in patients with recurrent glioblastoma: a phase 1 trial

10. Fc-enhanced anti-CTLA-4, anti-PD-1, doxorubicin, and ultrasound-mediated blood–brain barrier opening: A novel combinatorial immunotherapy regimen for gliomas.

12. Blood-Brain Barrier Opening with Ultrasound Augments Doxorubicin and Anti-PD-1 Therapy Efficacy, Intracranial Immune Activation, and Prolongs Survival in Preclinical Glioma Models

13. Neural stem cell delivery of an oncolytic adenovirus in newly diagnosed malignant glioma: a first-in-human, phase 1, dose-escalation trial

15. BIOM-15. CIRCULATING EXOSOMES CORRELATE WITH RADIOGRAPHIC PROGRESSION IN GLIOBLASTOMA PATIENTS AFTER ULTRASOUND-BASED OPENING OF THE BLOOD-BRAIN BARRIER

16. IMMU-21. LOW-INTENSITY PULSED ULTRASOUND PROMOTES THE PRESENTATION OF BRAIN-DERIVED ANTIGENS THROUGH ENHANCED TRAFFICKING OF ANTIGEN-PRESENTING CELLS FROM THE BRAIN INTO THE PERIPHERY

17. EXTH-24. FC-ENHANCED ANTI-CTLA-4 IMMUNE CHECKPOINT BLOCKADE AND ITS COMBINATION WITH ANTI-PD-1 WITH CONCOMITANT DOXORUBICIN AND ULTRASOUND-MEDIATED BBB OPENING: A NOVEL IMMUNOTHERAPY FOR GLIOBLASTOMA

18. Publisher Correction: ERK1/2 phosphorylation predicts survival following anti-PD-1 immunotherapy in recurrent glioblastoma

19. Motivational Interviewing: Improving Confidence With Self-care Management in Postoperative Thoracolumbar Spine Patients

20. 381 Repeated Opening of the Blood-Brain Barrier With the Skull-implantable SonoCloud-9 (SC9) Device: Phase 1 Trial of Nab-Paclitaxel and SC9 in Recurrent Glioblastoma

21. Data from Translocon-associated Protein Subunit SSR3 Determines and Predicts Susceptibility to Paclitaxel in Breast Cancer and Glioblastoma

22. Supplementary Figure from Translocon-associated Protein Subunit SSR3 Determines and Predicts Susceptibility to Paclitaxel in Breast Cancer and Glioblastoma

23. Supplementary Table from Translocon-associated Protein Subunit SSR3 Determines and Predicts Susceptibility to Paclitaxel in Breast Cancer and Glioblastoma

24. Supplementary Data from Translocon-associated Protein Subunit SSR3 Determines and Predicts Susceptibility to Paclitaxel in Breast Cancer and Glioblastoma

26. Mutant IDH1 and thrombosis in gliomas

27. Determining venous thromboembolism risk in patients with adult-type diffuse glioma

29. EPID-08. AGE-STRATIFIED SURVIVAL ANALYSES OF PHARMACOLOGICAL TREATMENTS IN PATIENTS WITH GLIOBLASTOMA

30. QOL-06. PREDICTING VENOUS THROMBOEMBOLISM IN PATIENTS WITH ADULT-TYPE DIFFUSE GLIOMAS

31. CTNI-37. REPEATED OPENING OF THE BLOOD-BRAIN BARRIER WITH THE SKULL-IMPLANTABLE SONOCLOUD-9 (SC9) DEVICE: PHASE 1 TRIAL OF NAB-PACLITAXEL AND SC9 IN RECURRENT GLIOBLASTOMA

33. Repeated opening of the blood-brain barrier with the skull-implantable SonoCloud-9 (SC9) device: Phase 1 trial of nab-paclitaxel and SC9 in recurrent glioblastoma.

37. A systematic review of pharmacologic treatment efficacy for depression in older patients with cancer

38. Large-field skull-implantable ultrasound opens the blood-brain-barrier leading to ultrastructural and transcriptional alterations in endothelium and enhanced drug penetration to the human brain: phase 1 trial using albumin-bound paclitaxel in recurrent glioblastoma

39. Combined immunotherapy with controlled interleukin-12 gene therapy and immune checkpoint blockade in recurrent glioblastoma: An open-label, multi-institutional phase I trial

40. BIOM-31. ERK1/2 PHOSPHORYLATION PREDICTS SURVIVAL FOLLOWING ANTI-PD-1 IMMUNOTHERAPY IN RECURRENT GLIOBLASTOMA

42. CTIM-20. FINAL RESULTS OF CONTROLLED IL-12 MONOTHERAPY AND IN COMBINATION WITH PD-1 INHIBITOR IN ADULT SUBJECTS WITH RECURRENT GLIOBLASTOMA

44. Combined immunotherapy with controlled interleukin-12 gene therapy and immune checkpoint blockade in recurrent glioblastoma: An open-label, multi-institutional phase I trial.

45. Disappearance of MMR-deficient subclones after controlled IL-12 and PD-1 inhibition in a glioma patient

46. The brain tumor not-for-profit and charity experience of COVID-19: reacting and adjusting to an unprecedented global pandemic in the 21st century

49. CTIM-05. COMBINATION OF CONTROLLED INTERLEUKIN-12 GENE THERAPY WITH IMMUNE CHECKPOINT BLOCKADE IN RECURRENT GLIOBLASTOMA: UPDATED RESULTS OF A MULTI-INSTITUTIONAL, OPEN LABEL PHASE 1 TRIAL

50. COVD-11. THE BRAIN TUMOR AND NOT FOR PROFIT AND CHARITY EXPERIENCE OF COVID 19: REACTING AND ADJUSTING TO AN UNPRECEDENTED GLOBAL PANDEMIC IN THE 21ST CENTURY

Catalog

Books, media, physical & digital resources